Stoke Therapeutics awards CEO Ian F. Smith $697K discretionary bonus for 2025

Stoke Therapeutics, Inc.

Discretionary bonus of $697,125 for CEO Ian F. Smith, equal to full target bonus for 2025.
Smith did not participate in 2025 annual bonus program; Board determined corporate goal achievement at 150% of target.
Bonus based on clinical and financial performance since Smith's appointment as interim CEO in March 2025 and permanent CEO in Oct 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.